Loading…
Loading…
EQUITY / NASDAQ · XNMS
Curanex Pharmaceuticals Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗4.9 USD · -2.5845%
Observed: Oct 1, 2026, 3:52 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 5.03 USD · Volume 1,187
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -3,325,560 USD | -57,658 USD | — |
| Net income | -3,290,970 USD | -60,346 USD | — |
| Cash and cash equivalents | 2,938,463 USD | — | — |
| Total liabilities | 286,254 USD | — | — |
| Total equity | 4,787,678 USD | 305,431 USD | +1,467.52% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 2,938,463 USD | — | — | — | 5,000,000 USD | 5,800,000 USD | — | — |
| Net incomeIncome statement | -3,290,970 USD | -6,441,198 USD | -3,150,228 USD | — | -4,225,106 USD | -954,059 USD | -1,151,988 USD | -60,346 USD |
| Operating profitIncome statement | -3,325,560 USD | -6,508,919 USD | — | — | -4,239,076 USD | -951,327 USD | -1,146,437 USD | -57,658 USD |
| Total assetsBalance sheet | 5,073,932 USD | — | — | 11,580,124 USD | 11,580,124 USD | 14,478,157 USD | — | — |
| Total equityBalance sheet | 4,787,678 USD | — | 8,078,648 USD | 11,219,084 USD | 11,219,084 USD | 14,292,202 USD | — | 305,431 USD |
| Total liabilitiesBalance sheet | 286,254 USD | — | — | 361,040 USD | 361,040 USD | 185,955 USD | — | — |
| Operating cash flowCash flow statement | — | -2,034,671 USD | — | — | -10,484,452 USD | — | -9,627,048 USD | — |
| Financing cash flowCash flow statement | — | — | — | — | 15,308,695 USD | — | 15,308,695 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/17/2025 | Open report ↗ Published: 11/17/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.